Discuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.
Trial purpose
The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.
|
national trial reference number | NCT05382325 |
|
Conditions |
Advanced Or Metastatic Solid Tumors
|
|
Age Range | 18+ |
|
Sex | All |
|
Current trial phase | 1 |
|
Trial start and end dates |
06-16-2022 07-31-2026 |
Trial locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.